Cencora (NYSE:COR) Issues Quarterly Earnings Results

Cencora (NYSE:COR) announced its quarterly earnings results on Wednesday. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04, FiscalAI reports. Cencora had a net margin of 0.48% and a return on equity of 227.15%. During the same period in the previous year, the business posted $3.73 EPS. The business’s revenue was up 5.5% compared to the same quarter last year.

Here are the key takeaways from Cencora’s conference call:

• Completed the acquisition of the majority stake in One Oncology (ownership now ~92%), adding a pharmaceutical-centric MSO platform to strengthen Cencora’s specialty and community oncology capabilities.
• Raised fiscal 2026 guidance: consolidated adjusted operating income growth to 11.5%–13.5%, U.S. Healthcare Solutions operating income to 14%–16%, and reaffirmed adjusted EPS guidance of $17.45–$17.75.
• Reported solid Q1 results with adjusted diluted EPS of $4.08 (+9%), consolidated revenue of $85.9B (+5.5%), and gross profit up 18%, driven mainly by U.S. Healthcare Solutions and recent acquisitions.
• Paused share repurchases to prioritize debt paydown after financing One Oncology; raised full-year interest expense guidance to $480M–$500M and recorded negative adjusted free cash flow of $2.4B in the quarter.
• International operating income declined (down ~14% as‑reported, ~17% on constant currency) due to timing of manufacturer price adjustments in a developing market, although management expects the timing issue to unwind and left full-year international guidance unchanged.

Cencora Price Performance

NYSE COR traded down $21.40 on Wednesday, hitting $340.35. 196,175 shares of the company were exchanged, compared to its average volume of 1,103,155. The company has a market cap of $66.02 billion, a P/E ratio of 42.78, a P/E/G ratio of 1.73 and a beta of 0.68. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. The firm has a 50 day moving average of $347.21 and a two-hundred day moving average of $325.24. Cencora has a 1-year low of $237.71 and a 1-year high of $377.54.

Insider Transactions at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. The trade was a 7.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the transaction, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 20,316 shares of company stock worth $7,151,265 in the last quarter. 0.38% of the stock is owned by company insiders.

Hedge Funds Weigh In On Cencora

A number of large investors have recently bought and sold shares of COR. Evergreen Capital Management LLC boosted its stake in shares of Cencora by 3.8% during the 2nd quarter. Evergreen Capital Management LLC now owns 1,233 shares of the company’s stock worth $370,000 after acquiring an additional 45 shares during the period. Prelude Capital Management LLC lifted its holdings in shares of Cencora by 2.7% during the 3rd quarter. Prelude Capital Management LLC now owns 2,208 shares of the company’s stock worth $690,000 after acquiring an additional 59 shares during the period. Ancora Advisors LLC raised its holdings in shares of Cencora by 1.5% during the 3rd quarter. Ancora Advisors LLC now owns 4,261 shares of the company’s stock worth $1,332,000 after buying an additional 64 shares in the last quarter. Modern Wealth Management LLC lifted its holdings in shares of Cencora by 7.6% in the second quarter. Modern Wealth Management LLC now owns 1,118 shares of the company’s stock worth $335,000 after acquiring an additional 79 shares during the last quarter. Finally, Keel Point LLC boosted its position in Cencora by 5.3% in the second quarter. Keel Point LLC now owns 1,632 shares of the company’s stock valued at $489,000 after buying an additional 82 shares in the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. JPMorgan Chase & Co. raised their price objective on Cencora from $344.00 to $417.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. UBS Group lifted their price target on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. TD Cowen boosted their target price on Cencora from $350.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Finally, Wells Fargo & Company upped their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $393.08.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.